All In Biotech

Drug Trial Radar · NCT05941507

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TROP2-Directed Antibody-Drug Conjugate LCB84, as a Single Agent and in Combination With an Anti-PD-1 Ab, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 5, 2023

Primary completion

Jan 2027

Study completion May 2027

Sponsor

Lead sponsor
LigaChem Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
AntibodyChem Biosciences, Inc.
First posted
Jul 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or RP2D of combination LCB84 and anti-PD-1 Ab, and to continue into dose expansion cohorts in select tumor types.

Conditions

  • Advanced Solid Tumors

Interventions

  • LCB84Drug

    TROP2-directed human monoclonal antibody (Ab) linked to a monomethyl auristatin E (MMAE) prodrug

  • Anti-PD-1 monoclonal antibodyDrug

    anti-PD-1 Ab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1 and 2)Time frame: Up to 48 months
  2. Recommended Phase 2 Dose of LCB84 alone and LCB84 in combination with an anti-PD-1 Ab (Phase 1)Time frame: Up to 24 months
  3. Objective Response Rate (Phase 2)Time frame: Up to 24 months
  4. Clinical Benefit Rate (Phase 2)Time frame: Up to 24 months
  5. Duration of Response (Phase 2)Time frame: Up to 24 months
  6. Time to Progression (Phase 2)Time frame: Up to 24 months
  7. Progression Free Survival (Phase 2)Time frame: Up to 24 months
  8. Overall Survival (Phase 2)Time frame: Up to 24 months

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Tennessee Oncology

    Nashville, Tennessee · Not yet recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Not yet recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.